Karolinska Cardiorenal Theme-centre and StockholmHeartbank (KKT)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01204645|
Recruitment Status : Recruiting
First Posted : September 17, 2010
Last Update Posted : June 15, 2017
Chronic kidney disease (CKD) affects 10-18% of the adult population and is becoming recognized as one of the most serious disorders causing increased risk for cardiovascular disease and death. In patients with ischemic heart disease 26% have increased creatinine, which rises to 40% if patients also have diabetes mellitus. Risk increases as renal function diminishes, and just slowing the rate of decline in renal function would have a tremendous impact on health and morbidity. This association is commonly termed the Cardiorenal Syndrome, though it is caused by a much more complex interplay between major pathogenetic pathways such as glucose metabolism and diabetes, systemic and tissue inflammation, tissue metabolism, coagulation, mineral metabolism, sympathetic activation, renin-angiotensin-aldosterone system activation, endothelial dysfunction, lipid metabolism, fetal programming etc.
Karolinska Institutet recently merged basic and clinical researchers in all these fields, creating a Karolinska Kardiorenal Theme Centre; ultimately aiming to explore the syndrome and provide improved care for the individual patient.
The investigators road to success:
- Creating a Biobank (blood, DNA, plasma) from the majority of all hosptalized patients with ACS in Stockholm county - Stockholmheartbank.
- This Theme Center include all teaching hospitals associated with Karolinska Institutet; Danderyd University Hospital, Karolinska University Hospital and Södersjukhuset University Hospital. Together theses hospitals serve as emergency hospitals for 1.9 million people. The investigators are aiming at creating a biobank from all patients admitted for an acute coronary event (about 2.300/yr), which is a unique asset for molecular and genetic research as well as observational and intervention studies.
- The investigators have access to the National registry with 100% coverage, that contains data on all patients admitted to Stockholms coronary care units since 1995.
- To ensure translation in to clinical practice, most of the researchers are also MD:s, and several are clinically active.
- The clinical network facilitates the development of novel therapies and translational research.
- Steering groups for Education and a Clinical Practice implementation program.
|Condition or disease|
|Chronic Kidney Disease Chronic Renal Failure Acute Coronary Syndrome Ischemic Heart Disease Myocardial Infarction|
|Study Type :||Observational|
|Estimated Enrollment :||10000 participants|
|Official Title:||Stockholmheartbank and Karolinska Cardiorenal Theme-centre, From Genome to Clinical Practice in Patients With Acute Coronary Syndrome and Impaired Kidney Function|
|Study Start Date :||May 2010|
|Estimated Primary Completion Date :||May 2022|
|Estimated Study Completion Date :||January 2024|
Acute Coronary Syndrome (ACS)
Continuous inclusion at emergency hospitals of patients with acute coronary syndrome (according to ESC/AHA definitions)
Patients included at 6 or 12 months follow-up visit after an acute coronary event.
Patients included when undergoing an coronary angiography for suspected or confirmed coronary heart disease
- Composite [ Time Frame: 1 year ]Combined endpoint of death, new cardiovascular event or dialysis.
- Renal function decline [ Time Frame: 5 year ]
- Vascular function [ Time Frame: 1 year ]Vascular function assessed by arterial stiffness, microcirculation by Laser-Doppler
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01204645
|Contact: Jonas Spaak, MD, PhD||+46 email@example.com|
|Danderyd University Hospital||Recruiting|
|Stockholm, Sweden, 18288|
|Contact: Jonas Spaak, MD, PhD +46 8 6557685 firstname.lastname@example.org|
|Study Director:||Jonas Spaak, MD PhD||Karolinska Institutet and Danderyd University Hospital|